# **Special Issue**

# New Trends in the Treatment of Neuropsychiatric Disorders

## Message from the Guest Editors

Neuropsychiatric disorders are conditions that involve both neurological and psychiatric symptoms, affecting cognition, emotion, and behavior. Common examples include depression, schizophrenia, bipolar disorder, and Alzheimer's disease, often resulting from complex interactions between genetic, biological, and environmental factors. This Special Issue will explore cutting-edge advances in the treatment of neuropsychiatric disorders, highlighting emerging therapeutic strategies and innovative research. It will cover a broad range of topics, including novel pharmacological agents, neuromodulation techniques (such as transcranial magnetic stimulation and deep brain stimulation), and personalized medicine approaches informed by genetics and biomarkers. This Special Issue will also emphasize the role of digital therapeutics, Al-driven diagnostics, and integrative models that combine psychological, neurobiological, and social perspectives. Together, these contributions reflect a paradigm shift toward more targeted, effective, and individualized care for conditions such as depression, schizophrenia, bipolar disorder, and anxiety.

## **Guest Editors**

Dr. Terezia Kiskova-Simkova

Institute of Pathology, Faculty of Medicine, Pavol Jozef Safarik University, 040 01 Kosice, Slovakia

#### Dr. Aneta Bednarova

Department of Psychiatry, Faculty of Medicine, Pavol Jozef Safarik University and University Hospital of L. Pasteur, Kosice, Slovakia

## Deadline for manuscript submissions

30 April 2026



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/256478

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Editor-in-Chief

## Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

## Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

